Invivyd
Senior Director, Head of Clinical Operations
Join to apply for the Senior Director, Head of Clinical Operations role at Invivyd.
About Us There are more than 9 million immunocompromised people in the United States. Almost half a million of those represent a population that are moderately to severely immunocompromised and at highest risk for severe COVID‑19, including stem cell and solid organ transplant patients as well as those with hematologic cancers. At Invivyd, Inc., we take those numbers very seriously and work each day on a mission to deliver protection from serious viral infectious diseases, beginning with SARS‑CoV‑2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best‑in‑class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody in its pipeline of innovative antibody candidates. In October 2025, the FDA cleared the company’s Investigational New Drug (IND) application and provided feedback to advance the company’s REVOLUTION clinical program, Invivyd’s development program for VYD2311, a vaccine alternative monoclonal antibody candidate for the prevention of COVID. Join an incredible team that thrives in a start‑up environment, embraces ownership, impacts patients and families, thinks boldly, takes calculated risks, is unafraid of failure, and welcomes change as a catalyst for growth.
#J-18808-Ljbffr
About Us There are more than 9 million immunocompromised people in the United States. Almost half a million of those represent a population that are moderately to severely immunocompromised and at highest risk for severe COVID‑19, including stem cell and solid organ transplant patients as well as those with hematologic cancers. At Invivyd, Inc., we take those numbers very seriously and work each day on a mission to deliver protection from serious viral infectious diseases, beginning with SARS‑CoV‑2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best‑in‑class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody in its pipeline of innovative antibody candidates. In October 2025, the FDA cleared the company’s Investigational New Drug (IND) application and provided feedback to advance the company’s REVOLUTION clinical program, Invivyd’s development program for VYD2311, a vaccine alternative monoclonal antibody candidate for the prevention of COVID. Join an incredible team that thrives in a start‑up environment, embraces ownership, impacts patients and families, thinks boldly, takes calculated risks, is unafraid of failure, and welcomes change as a catalyst for growth.
#J-18808-Ljbffr